Stephen R. Pratt

Stephen-Pratt

Stephen R. Pratt

Partner

Philadelphia | Cira Centre, 2929 Arch Street, Philadelphia, PA, United States of America 19104-2808
+1 215 994 2296 | +1 215 994 2222

New York | Three Bryant Park, 1095 Avenue of the Americas, New York, NY, United States of America 10036-6797
+1 646 731 6135 | +1 212 698 3599

| vCard | PDF

Stephen R. Pratt focuses his practice on mergers and acquisitions, with an emphasis on private equity and public company M&A, as well as securities offerings and general corporate matters, including corporate governance matters and public company reporting and disclosure issues.

Mr. Pratt has advised strategic buyers and sellers, private equity sponsors, special committees and financial advisors on merger and acquisition transactions, with representations in a wide range of industries including banking, financial services, manufacturing, biotechnology, real estate, telecommunications, aviation, gaming and medical devices.

He also regularly advises alternative asset managers on fund formation and regulatory and operational issues involving business development companies and other permanent capital vehicles, including issues concerning joint ventures and other strategic transactions.

Experience
  • One Equity Partners on its acquisition of Anvil International, a leading North American manufacturer of pipe fitting and system components from Mueller Water Products (NYSE:MWA), on its acquisition of a majority interest in The W.W. Williams Company and in a number of buyout and exit transactions, as well as advising a number of portfolio companies on add-on acquisitions.
  • Numerous business development companies sponsored by FS Investments in connection with their multi-billion dollar continuous equity offerings, debt offerings and general corporate and securities matters.
  • Stifel Financial Corp. on its acquisition of Eaton Partners, LLC and in connection with Stifel Aviation Finance, a series of aircraft specialty finance vehicles.
  • Edge Therapeutics, a U.S.-based biotechnology company, in connection with its pending merger with PDS Biotechnology Corporation, a privately-held, clinical-stage cancer immunotherapy company.
  • Aviragen Therapeutics, Inc. (formerly NASDAQ:AVIR), a biopharmaceutical company that had been focused on the discovery and development of products to prevent and treat infectious diseases, in its merger with Vaxart, Inc. (NASDAQ:VXRT).
  • Berwind Group on the sale of Specialty Coating Systems to KISCO Ltd. of Japan.
  • CDI Corp. on its acquisition of EdgeRock Technologies, LLC.
  • Celgene Corporation on its collaboration with Sutro BioPharma.
  • Macquarie Corporate and Asset Finance on its sale of a BNSF Logistics Facility to funds managed by CRIC2 Funds, LLC.
Education
  • Boston College, B.S., 2005
  • University of Pennsylvania Law School, J.D., 2010, cum laude, Articles Editor for the University of Pennsylvania Journal of Business Law
Admissions
  • Pennsylvania
  • New York
Clerkships
  • Delaware Court of Chancery, Honorable John W. Noble
Memberships
  • Philadelphia Bar Association